Dec. 6, 2021

Winship researchers to present at San Antonio Breast Cancer Symposium

Photo of Winship researchers to present at San Antonio Breast Cancer Symposium

Leading physicians, researchers and students from Winship will present their work at the 44th annual San Antonio Breast Cancer Symposium which will take place in San Antonio, Texas on Dec. 7-10. (Illustration: SABCS)

Leading physicians, researchers and students from Winship Cancer Institute of Emory University (Winship) will present their work at the 44th annual San Antonio Breast Cancer Symposium which will take place in San Antonio, Texas on Dec. 7-10.

Kevin Kalinsky, MD, MS, director of Winship's Glenn Family Breast Center, will provide updated analyses from a study published Dec. 1 in The New England Journal of Medicine.

The RxPONDER study established that postmenopausal women with certain types of breast cancer can forgo chemotherapy and rely on hormone therapy instead. Kalinsky has called the results "practice changing."

Kalinsky is joining colleagues in presenting two other studies. One covers the use of oral selective estrogen receptor degraders in women with some types of breast cancer. The other involves the use of drugs to treat hormone receptor-positive, HER2-negative metastatic breast cancers.

Kalinsky is also part of an SABCS career development session on Dec. 8 and is chairing a spotlight poster session on Dec. 9.

"At this symposium, the top breast cancer researchers and physicians in the world come together and share the latest advances in the field," Kalinsky says. "Winship's team is excited to again be a part of SABCS as we work to provide our patients with unparalleled cancer care."

Other Winship experts at SABCS include:

Sunil S. Badve, MD, vice chair of the cancer pathology program in Emory’s Department of Pathology and Laboratory Medicine, is part of a group discussing clinical trials aimed at treating triple negative breast cancer.

Jane Meisel, MD, will discuss the use of the Oncotype DX Breast Recurrence Score to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor positive breast cancer.

A group of Winship researchers, led by Mylin Torres, MD, will discuss the use of polygenic risk scores to predict toxicities in racially diverse breast cancer patients following radiotherapy, The other Winship authors are Tian Liu, PhD, Boran Zhou, Xiaofeng Yang, PhD, Gabrielle Brown, India Green, Andrew Miller, MD, and Jingjing Yang, PhD.

Ritu Aneja, PhD, associate professor of biology at Georgia State University and a member of Winship's Cell and Molecular Biology Research Program, is also a lead author of three studies at the conference.

 

Cascade Link  TOP